Founder to focus on products
White replaced in Collagen boardroom shake-up
Jamal D. Rushdy has been installed as chief executive, replacing company founder Stewart White who will spearhead the Glasgow firm’s product development as chief scientific officer (CSO).
Mr. Rushdy’s initial appointment as chief business officer was announced last November 2015. He has more than 20 years’ experience in the medical device arena, specifically within two mid-size high growth public companies and three successful start-ups.
The company said he has a track record of building businesses with successful exits and transforming organisations through integration and performance improvement, adding value through business development and leadership.
Prior to Collagen Solutions, Mr Rushdy was a vice president at Tornier Inc, a Minneapolis orthopaedics and biologics company where he served in various leadership roles in U.S. sales operations, global sports medicine and biologics marketing, and business and corporate development. Mr. Rushdy also played a key role in Tornier’s 2011 Initial Public Offering.
As CSO, Dr. White, now leads R&D and corporate development and will focus on the company’s product development and innovation platform.
The company has also announced income of £3.2 million for the year ending 31 March which exceeds prior guidance of £2.8 million.
It said the results have been in part driven by the early benefits of the company’s implementation of an improved sales process, together with achievement of global sales and integration synergies. Collagen now has dedicated sales people in Europe, Asia, and North America.
Commenting on the management changes, David Evans, chairman said: “I would like to thank Stewart for his tireless efforts to develop a strong biomaterials Company. As the CSO, I believe he will bring focus and leadership to our innovation platform.
“As we look ahead to the need for Collagen Solution’s continued growth, we are pleased that Jamal has agreed to take on this additional responsibility. Jamal’s experience in global medical technology organisations, and his contribution and recent track record with our company, gives us confidence that he will continue the momentum and execution of our strategic initiatives.”
Mr Rushdy said: “I am excited about the strategy we are pursuing to achieve a leading position in the biomaterials and regenerative medicine market.”